BR112021026597A2 - Administração intranasal de dantroleno para tratamento contra doença de alzheimer - Google Patents
Administração intranasal de dantroleno para tratamento contra doença de alzheimerInfo
- Publication number
- BR112021026597A2 BR112021026597A2 BR112021026597A BR112021026597A BR112021026597A2 BR 112021026597 A2 BR112021026597 A2 BR 112021026597A2 BR 112021026597 A BR112021026597 A BR 112021026597A BR 112021026597 A BR112021026597 A BR 112021026597A BR 112021026597 A2 BR112021026597 A2 BR 112021026597A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- dantrolene
- alzheimer
- disease
- onset
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
administração intranasal de dantroleno para tratamento contra doença de alzheimer. trata-se de métodos para inibir neurogênese e/ou sinaptogênese comprometidas em neurônios em um indivíduo que tem ou suspeita ter doença de alzheimer (ad), métodos para aprimorar e/ou retardar o declínio da função cognitiva após o início da neuropatologia e disfunção cognitiva, em que a neuropatologia e as disfunções cognitivas são causadas por ad, de métodos para aprimorar e/ou retardar o declínio da memória antes do início dos sintomas de ad, de métodos para aumentar a concentração e a duração do dantroleno no cérebro e métodos para aprimorar e/ou retardar o declínio da memória após o início dos sintomas de ad, sendo que os métodos compreendem administrar por via intranasal a um indivíduo com necessidade do mesmo uma quantidade de uma composição farmacêutica que compreende dantroleno eficaz para inibir a ativação exacerbada do receptor n-metil-d-aspartato (nmda) e/ou do receptor de rianodina (ryr). os métodos compreendem adicionalmente administrar uma quantidade terapeuticamente eficaz de um antagonista do receptor de glutamato ao indivíduo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868820P | 2019-06-28 | 2019-06-28 | |
| PCT/US2020/040198 WO2020264531A1 (en) | 2019-06-28 | 2020-06-29 | Intranasal dantrolene administration for treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021026597A2 true BR112021026597A2 (pt) | 2022-03-15 |
Family
ID=74059636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021026597A BR112021026597A2 (pt) | 2019-06-28 | 2020-06-29 | Administração intranasal de dantroleno para tratamento contra doença de alzheimer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220354827A1 (pt) |
| EP (1) | EP3989969A4 (pt) |
| JP (1) | JP2022538608A (pt) |
| KR (1) | KR20220047970A (pt) |
| CN (1) | CN114828848A (pt) |
| AU (1) | AU2020302992A1 (pt) |
| BR (1) | BR112021026597A2 (pt) |
| CA (1) | CA3145528A1 (pt) |
| MX (1) | MX2022000231A (pt) |
| WO (1) | WO2020264531A1 (pt) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7758890B2 (en) * | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| US7732162B2 (en) * | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| JP5666087B2 (ja) * | 2005-04-06 | 2015-02-12 | アダマス・ファーマシューティカルズ・インコーポレーテッド | Ｃｎｓ関連疾患の治療のための方法及び組成物 |
-
2020
- 2020-06-29 US US17/623,246 patent/US20220354827A1/en active Pending
- 2020-06-29 CN CN202080054348.2A patent/CN114828848A/zh active Pending
- 2020-06-29 WO PCT/US2020/040198 patent/WO2020264531A1/en active Application Filing
- 2020-06-29 AU AU2020302992A patent/AU2020302992A1/en active Pending
- 2020-06-29 EP EP20833145.4A patent/EP3989969A4/en active Pending
- 2020-06-29 CA CA3145528A patent/CA3145528A1/en active Pending
- 2020-06-29 KR KR1020227003375A patent/KR20220047970A/ko unknown
- 2020-06-29 BR BR112021026597A patent/BR112021026597A2/pt unknown
- 2020-06-29 JP JP2021577376A patent/JP2022538608A/ja active Pending
- 2020-06-29 MX MX2022000231A patent/MX2022000231A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020264531A1 (en) | 2020-12-30 |
| CN114828848A (zh) | 2022-07-29 |
| EP3989969A4 (en) | 2023-06-07 |
| US20220354827A1 (en) | 2022-11-10 |
| MX2022000231A (es) | 2022-04-20 |
| CA3145528A1 (en) | 2020-12-30 |
| JP2022538608A (ja) | 2022-09-05 |
| KR20220047970A (ko) | 2022-04-19 |
| AU2020302992A1 (en) | 2022-02-03 |
| EP3989969A1 (en) | 2022-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| BR112018005454A2 (pt) | administração de potencializadores de cftr deuterados | |
| MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
| TR201903603T4 (tr) | Hareket bozukluklarının tedavisinde kullanım için A2A reseptörü antagonistleri. | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| CL2021001609A1 (es) | Régimen de dosificación y combinación farmacéutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona | |
| MX2022001565A (es) | Formas solidas de un estimulador de guanilato ciclasa soluble (sgc). | |
| EA201991147A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| GT200900173A (es) | Dispersión sólida de un antagonista de neuroquinina | |
| MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
| BR112018014661A2 (pt) | composição e composição para uso | |
| EA201891416A1 (ru) | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА | |
| BR112021023110A2 (pt) | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton | |
| BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
| EA201890590A1 (ru) | Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии | |
| EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | |
| BR112021026597A2 (pt) | Administração intranasal de dantroleno para tratamento contra doença de alzheimer | |
| WO2016130518A3 (en) | Methods and compositions for treating muscle disease and disorders | |
| FI3600276T3 (fi) | Betahistiini tai sen farmaseuttisesti hyväksyttävä suola ja monoamiinioksidaasin inhibiittori käytettäväksi yhden tai useamman huimausoireen hoitamisessa tai ehkäisemisessä kohteessa | |
| Miklya | Essential difference between the pharmacological spectrum of (−)-deprenyl and rasagiline | |
| EA201792170A1 (ru) | Производные индола |